Zepbound Results: What the Trials Actually Show, Dose by Dose

Two FDA approvals sit under the Zepbound name now, not one, and that's the detail that separates this page from a general rundown of tirzepatide results. The molecule is identical to Mounjaro's, but the brand carries its own trial program, its own sleep-apnea approval, and its own answer to a question a lot of women ask before a prescriber ever writes the script: does that low starting dose actually do anything, or is it just there to slow you down?

How much weight does Zepbound actually help you lose, on average?

SURMOUNT-1 is still the source everything else gets measured against. Over 72 weeks, adults without diabetes lost an average of about 15% of starting body weight on the 5mg maintenance dose. That climbed to roughly 19.5% on 10mg, and close to 21% on the maximum 15mg dose. Placebo, over the same stretch, moved about 3%. Those numbers count everyone assigned to a dose, including people who stopped early or never tolerated it well, so they're a conservative floor rather than a best-case number.

An average also flattens a real spread of individual results. In the same trial, the large majority of people on 5mg and nearly everyone on 10mg or 15mg lost at least 5% of their weight — the threshold generally used to call a weight-loss drug 'working' — against a much smaller share on placebo. On the higher end, different published analyses of SURMOUNT-1 put roughly a third to nearly 40% of people on the 10mg or 15mg doses crossing 25% or more, a result placebo essentially never produced. Landing under the headline average doesn't mean the drug failed on you; it means your number sits somewhere in a distribution that a single quoted percentage never shows.

Does the 2.5mg starting dose actually cause weight loss, or is it just for adjustment?

Mostly the latter, and SURMOUNT-1's own design says so directly. Everyone randomized into an active-drug arm of that trial — whether they ended up at 5mg, 10mg, or 15mg — started at 2.5mg for the first four weeks and stepped up from there. It was never tested or reported as its own separate treatment arm, so there's no honest trial figure that says '2.5mg produces X% weight loss' the way there is for the three maintenance doses above it. If a page or a provider quotes you one, it isn't coming from this trial.

What the low starting dose is actually doing is giving the gut time to adjust to a new hormone signal before the level climbs, which is also why nausea and other digestive side effects tend to be worst in the first few weeks and ease as the body catches up. Appetite is usually the first thing that shifts on this dose — food noise quiets, or a normal portion starts feeling like enough — often before the scale reflects much of anything. A quiet scale in month one is the schedule working as designed, not the medication doing nothing.

What is Zepbound approved for besides weight loss?

This is where the brand name stops being interchangeable with Mounjaro. On December 20, 2024, the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity — the first medication ever approved for that condition, and an indication that sits on Zepbound's label specifically, not on Mounjaro's. The approval rested on two SURMOUNT-OSA trials: in one, Zepbound reduced the apnea-hypopnea index by an average of about 25 events per hour, against about 5 on placebo; in the other, the reduction ran to about 29 events per hour, against roughly 6 on placebo. A meaningfully larger share of people on Zepbound reached remission or only mild, non-symptomatic sleep apnea by the end of each trial than on placebo — roughly 42% versus 16% in the first study, and about 50% versus 14% in the second.

That trial data also tracked cardiometabolic markers — blood pressure and sleep-quality measures among them — as secondary findings alongside the AHI results, which is worth knowing but shouldn't be stretched further than the label supports. Zepbound does not currently carry an FDA-approved indication for reducing heart attack, stroke, or cardiovascular death. That specific approval landed elsewhere in 2026 — on Mounjaro's label, tied to type 2 diabetes and a trial called SURPASS-CVOT — and it doesn't transfer to Zepbound's obesity-focused approval. A separate trial, SURMOUNT-MMO, is currently testing tirzepatide for cardiovascular and mortality outcomes specifically in people with obesity who don't have diabetes, but it's an ongoing, event-driven study without results yet. Anyone telling you Zepbound is already approved to protect your heart is ahead of what the FDA has actually cleared.

What does a realistic month-by-month timeline look like?

The schedule below tracks the dose climbing roughly every four weeks, not a fixed calendar — a prescriber holding you on a step longer for tolerability pushes every later checkpoint out along with it.

• Month 1, on the 2.5mg starting dose: appetite is usually the first thing that shifts while the scale barely moves — this step exists for tolerability, not results.
• Month 3 (around week 12): the checkpoint SURMOUNT-1's own post hoc data actually tracks. A large majority of people had already lost at least 5% of their weight by here in that trial; most of the rest caught up over the following months rather than staying stuck.
• Month 6: many people are still climbing the dose ladder around this point, since reaching 15mg on the standard schedule takes at least five months, so the scale is usually still moving. Time-to-plateau research puts the median around six to nine months depending on where someone started.
• Months 12 to 18 (around week 72): this is where SURMOUNT-1 measured its headline numbers — about 15% at 5mg, about 19.5% at 10mg, and close to 21% at 15mg.
• Beyond 18 months: loss tends to hold rather than keep climbing, evidence of a plateau settling in rather than the medication losing its grip.

What do real before-and-after numbers show — not transformation photos?

Strip the marketing away and 'before and after' really means three response bands, each represented by real trial participants rather than a single curated photo. A minority land under 5% loss and are generally considered non-responders — a rate that also shows up on placebo through the ordinary noise of diet and metabolism. Most people land in a moderate band, somewhere between 5% and 15% of body weight. And a meaningful share at the higher doses cross 25% or more and would be called super-responders — depending on which SURMOUNT-1 analysis is being read, that's roughly a third to nearly 40% of people.

None of these bands is a verdict on effort. Response tracks the dose actually reached, receptor sensitivity and genetics that don't show up on an intake form, and how consistently the weekly injection goes in. A photo online can't show you any of that; a number tied to a specific week and dose can.

Is Zepbound's tirzepatide different from Mounjaro's results?

Not in the body — the active ingredient, the dose ladder, and the manufacturer are all identical. What differs is the FDA approval and trial basis attached to each name: Zepbound leans on SURMOUNT-1 for weight management and on SURMOUNT-OSA for sleep apnea, while Mounjaro leans on the separate SURPASS trials for type 2 diabetes and, as of August 2026, on SURPASS-CVOT for cardiovascular risk reduction in that same diabetic population. A prescriber can write either off-label for the other's use, but the label — and the insurance door it opens — doesn't transfer between them. Zepbound alternatives, including Mounjaro covers that price-and-access comparison in full, and tirzepatide results covers the broader molecule-level numbers behind both brands if you're weighing them side by side rather than looking at Zepbound specifically.

Why might results at 40-plus, in perimenopause, look different?

This has actually been studied directly rather than left to guesswork. A 2025 post hoc analysis of the SURMOUNT program, published in the journal Obesity, broke tirzepatide's weight-loss results down by reproductive stage. Premenopausal and perimenopausal women lost close to 20% of body weight after 18 months. Postmenopausal women who had never used hormone therapy lost somewhat less. Postmenopausal women using hormone therapy alongside tirzepatide, though, landed back close to that premenopausal number rather than trailing behind it.

Falling estrogen is the likely mechanism behind the gap on its own: it shifts fat toward the abdomen and works against insulin sensitivity, adding friction to the same appetite and metabolic pathways tirzepatide acts on. Worth being precise about what that hormone-therapy finding does and doesn't mean, though — it comes from a retrospective cohort, not a randomized trial designed to test the combination, so it's a real association worth raising with a clinician rather than a settled instruction to add hormone therapy for a bigger number on Zepbound. Hormone therapy is its own decision, answering its own set of symptoms and risks — GLP-1 and menopause covers how the two fit together, and where they solve different problems rather than compete for the same one.

What actually determines your individual result?

Trial averages explain the shape of the curve. They don't predict your specific number. A handful of factors reliably move it in real practice:

• The dose you actually reach and tolerate: SURMOUNT-1's own numbers show several points of gap between the 5mg and 15mg groups, and reaching a higher maintenance dose, tolerability allowing, generally means more loss.
• How consistently you take it: a missed or delayed weekly dose interrupts the steady drug level these medications depend on — a variable the trial controlled for that daily life doesn't.
• Where you started: starting weight and metabolic health shape both how much percentage loss is realistic and how the body responds along the way, which is biology, not a personal shortfall.
• Whether you hit the 'working' threshold within three months: losing at least 5% by then is the checkpoint the trial data itself tracks, and falling well short of it is usually the point a dose conversation happens rather than a reason to wait indefinitely.
• Individual variation that isn't fully mapped yet: some of the spread between minimal and super-responders comes down to genetics and receptor sensitivity researchers are still sorting out.

Is a weight plateau normal, or has Zepbound stopped working?

Normal, and the data even puts a rough number on when to expect one. A 2025 analysis of SURMOUNT-1 and SURMOUNT-4 found the median time to reach a weight plateau — defined as less than 5% further change over a 12-week stretch — ran from about 24 weeks for people who started at a lower BMI category up to about 36 weeks for people who started at a higher one. By week 72, the large majority of participants across every BMI group — roughly 88% to 90% — had reached that plateau.

A plateau isn't the drug quietly failing; it's closer to a body settling at a new stable weight once the dose has been at its ceiling for a while, the same pattern that shows up after most successful weight-loss methods. What's genuinely different from a healthy plateau is weight actively climbing back up on an unchanged dose — that pattern is worth raising with a prescriber sooner rather than later, since it isn't what the plateau data describes as expected.

Does the weight — or the sleep apnea benefit — come back if you stop?

For weight, yes, at least partly, and the trial built specifically to test this is direct about it. SURMOUNT-4 had participants spend 36 weeks on tirzepatide first, reaching an average of about 21% weight loss, then randomized them to either continue the medication or switch to placebo for another year. The group that continued lost an additional 5.5% on average over that year. The group switched to placebo regained an average of 14% of their body weight over the same period — though most still ended the trial well below where they'd started, since that regain came off a much larger initial loss.

For the sleep apnea benefit specifically, the honest answer is that off-drug durability hasn't been studied the way the weight regain has. SURMOUNT-OSA measured AHI improvements while participants stayed on Zepbound; it wasn't designed to follow what happens to breathing patterns after stopping, and no published data fills that gap as of this writing. Given how closely tied obstructive sleep apnea is to excess weight, and how reliably weight tends to return after stopping tirzepatide, it would be reasonable to expect at least some of the sleep-apnea improvement to erode alongside the weight that comes back — but that's a mechanistic inference, not a measured trial result, and it's worth stating plainly as a gap in the evidence rather than filling it with a number that doesn't exist yet.

What does this cost, and where do you actually start?

Cost varies enough by dose, insurance, and whether your plan recognizes obesity or sleep apnea as a covered diagnosis that a single number here would undersell the real range. Zepbound's on-label status for both weight management and sleep apnea gives it a real shot at coverage and at Eli Lilly's own savings programs that off-label uses generally don't get.